AGI Therapeutics reports interim loss

Dublin based pharmaceutical company AGI Therapeutics has announced a pre-tax loss of $7.46m (€5.2m) for the six months to the end of June 2008. This compares to a loss of $8.9m (€6.2m) the same time last year.

The company, which focuses on gastrointestinal drug products, said its revenues for the six month period were unchanged at $288,000 (€203,828). The company also spent $8.3m (€5.8m) on research and development in the first half of the year.